New Paragraph

New Blog Posts
-
May's Topic is Medical Management
Medical Management means using medicines and other non-invasive therapies to relieve symptoms of hypertrophic cardiomyopathy and other thick heart diseases. Knowing what is out there and what is being studied will help you navigate your treatment with your healthcare providers.
-
US FDA Updates Camzyos Label for oHCM
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications for Obstructive HCM
-
Camzyos® receives manufacturing and marketing approval for oHCM in Japan
Bristol-Myers Squibb Company announced today that it has received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare for the selective cardiac myosin inhibitor Camzyos® Capsules (mavacamten) 1mg, 2.5mg, and 5mg for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).
-
Decisions in HCM
by Victoria-Theresa Wyatt and Gordon Fox: The first in a series
This series will help you to identify, analyze and evaluate important decisions you will have to make as you navigate life with HCM.
-
April's Topic is Genetic Testing
Who should have genetic testing, and when?
Suppose you have been diagnosed with HCM through an EKG, echocardiogram, and a visit with a cardiologist. Most experts recommend that you have genetic testing to know for sure why your heart is too thick.
-
Arrhythmia is the HCMA topic for March
Some arrhythmias are harmless, while others are serious and need treatment. Health Educator Sabrina Cuddy discusses common arrhythmias in HCM, like atrial flutter/fibrillation, ventricular tachycardia/fibrillation, left or right bundle branch block, PVC, PAC, and others.
-
COVID-19 vaccine with HCM?List Item 1
HCMA Board member Gordon Fox, MD, helps us understand the the potential the risks and benefits and why the HCMA suggests gettin the COVID vaccine for patients with HCM.
-
Camzyos is SafeList Item 2
Camzyos eliminates (or greatly reduces) obstruction in a majority patients; the risk of heart failure is relatively low; and the REMS program is effective at protecting patients from severe heart failure and its consequences, says HCMA Board member Gordon Fox, MD.
Older Posts

